Register For More Information

To help us keep you informed about the latest BROVANA® developments, please register below.

First Name
Last Name
E-mail
I am a
Keep me updated with information from Sepracor about COPD and BROVANA®
Click here for important privacy information.

Related Links

  Click here for a list of home healthcare or retail pharmacies filling BROVANA for Medicare Part B patients
 
Complete Prescribing Information
including Boxed Warning
 
Patient's Medication Guide
 
Patient Assistance Program

No Warranty
Information accessed through this web site is presented in summary and interactive form and is not exhaustive. Sepracor Inc. makes no warranties or representations as to its accuracy or completeness. This information is provided "as is" without warranty of any kind, either express or implied, including but not limited to implied warranties of merchantability, fitness for particular purpose, or non-infringement. Some jurisdictions do not allow exclusion of implied warranties so the above exclusion may not apply to you. Certain links on this site lead to sites or sources located on servers maintained by third parties over which Sepracor has no control. Sepracor makes no representation as to the accuracy or any other aspect of the information contained in or on such sites, sources or servers, nor does Sepracor necessarily endorse such sites or sources. Neither Sepracor nor its affiliates or their respective employees shall be liable in any way for any legal claims, whether in contract, tort or otherwise in any way connected with the use or performance of this web site or any information linked or referenced by this site or any other information or World Wide Web site which link to this site.

The information included in (or accessible from) this web site contains forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy, potential benefits, and successful development of the company's pharmaceuticals under development. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the submission, acceptance, and approval of regulatory filings; the results of clinical trials with respect to products under development; the scope of the company's patent protection with respect to such product candidates; the commercial success of Sepracor's products; the ability of the company to attract and retain qualified personnel; the performance of Sepracor's licensees; the availability of sufficient funds to continue research and development efforts; and certain other factors that may affect future operating results and are detailed in the company's periodic reports filed with the Securities and Exchange Commission.

NON-COMMERCIAL USE
Sepracor gives you permission to copy pages of www.brovana.com documents published herein on the World Wide Web for non-commercial use only, provided any copy of these documents that you make shall retain all copyright and other proprietary notices and any disclaimers contained herein.

COPYRIGHTS/TRADEMARKS
All images, trademarks and text are the property of Sepracor and may not be downloaded, distributed, sorted, reused, reported, modified or otherwise used except as provided herein, without the express written permission of Sepracor Inc. All product and service names appearing in a typeface different from that of the surrounding text or with a trademark symbol, including "Sepracor" logo, are trademarks and service marks owned by Sepracor Inc. or its subsidiaries or affiliates or another company. Use of these marks, except as permitted herein, is expressly prohibited. Nothing contained herein shall be construed as conferring, by implication, estoppel or otherwise, any license or right under any patent or trademark of Sepracor or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Sepracor copyright.

NO CONFIDENTIALITY
No confidential relationship shall be established in the event that any user of this World Wide Web site should make any oral, written or electronic response to Sepracor (such as feedback, questions, comments, suggestions, ideas, etc.). Such response and any information submitted therewith shall be considered non-confidential, and Sepracor shall be free to reproduce, publish or otherwise use such information for any purposes whatsoever including, without limitation, the research, development, manufacture, use or sale of products incorporating such information. The sender of any information to Sepracor is fully responsible for its content, including its truthfulness and accuracy and its non-infringement of any other person's proprietary rights.

INDIVIDUAL USAGE OF MEDICAL PRODUCTS
The information provided via this web site concerning medical products is not complete and should not be used as a substitute for a consultation or visit with a physician or other health care provider. Should you have any health care related questions, please see your physician or other health care provider promptly.

Sepracor Inc. may, at any time, revise these Terms and Conditions by updating this page. You are bound by any such revisions and should therefore periodically visit this page to review the then current Terms and Conditions.

         
 

Home | Terms of Use | Privacy Statement | Important Safety Information | Contact Us

©2008 Sepracor Inc. All rights reserved
 
Important Safety Information
Long-acting beta2-adrenergic agonists may increase the risk of asthma related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma related deaths in patients receiving salmeterol. This finding with salmeterol may apply to arformoterol (a long-acting beta2-adrenergic agonist), the active ingredient in BROVANA.

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.

BROVANA should not be used in conjunction with other inhaled, long-acting beta2- agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines. BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The most common adverse events reported in patients taking BROVANA, and occurring more frequently than patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient. BROVANA is a medicine used to treat COPD. Remember that no medicine is for everyone. Only your doctor can prescribe BROVANA for you.